Cargando…
On the Single-Crystal Structure of Tenofovir Alafenamide Mono-Fumarate: A Metastable Phase Featuring a Mixture of Co-Crystal and Salt
Tenofovir alafenamide (TAF) is a prodrug of tenofovir as a potent nucleotide reverse transcriptase inhibitor. It serves as the key component of Genvoya(®) for the first-line treatment of human immunodeficiency virus infection (HIV) and is the active component of Vemlidy(®) for the treatment of chron...
Autores principales: | Wang, Jian-Wei, Liu, Lu, Yu, Ka-Xi, Bai, Hong-Zhen, Zhou, Jun, Zhang, Wen-Hua, Hu, Xiurong, Tang, Guping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730268/ https://www.ncbi.nlm.nih.gov/pubmed/33287166 http://dx.doi.org/10.3390/ijms21239213 |
Ejemplares similares
-
Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
por: Lengauer, Hannes, et al.
Publicado: (2020) -
A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil
Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020) -
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
por: Funderburg, Nicholas T., et al.
Publicado: (2016) -
Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Michienzi, Sarah M, et al.
Publicado: (2021) -
Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)